Zestoretic (LISINOPRIL AND HYDROCHLOROTHIAZIDE)
Zestoretic (LISINOPRIL AND HYDROCHLOROTHIAZIDE) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Zestoretic; Generic name: LISINOPRIL AND HYDROCHLOROTHIAZIDE; Drug class: Thiazide Diuretic [EPC].
| Brand name | Zestoretic |
|---|---|
| Generic name | LISINOPRIL AND HYDROCHLOROTHIAZIDE |
| Drug class | Thiazide Diuretic [EPC] |
| Manufacturer | Almatica Pharma Inc. |
| Used for | INDICATIONS AND USAGE ZESTORETIC is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve b |
| Dosage | DOSAGE AND ADMINISTRATION Lisinopril monotherapy is an effective treatment of hypertension in once-daily doses of 10 mg to 80 mg, while hydrochlorothiazide monotherapy is effective in doses of 12.5 mg per day to 50 mg per day. In clinical trials of lisinopril/hydrochlorothiazide combination therapy using lisinopril doses of 10 mg to 80 mg and hydrochlorothiazide doses of 6.25 mg to 50 mg, the antihypertensive response rates generally increased with increasing dose of either component. The side e |
| Warnings | WARNINGS Lisinopril Anaphylactoid and Possibly Related Reactions: Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including ZESTORETIC) may be subject to a variety of adverse reactions, some of them serious. Head and Neck Angioedema: Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin-con |
| Active ingredient(s) | HYDROCHLOROTHIAZIDE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0d3a966f-f937-05a8-a90f-5aa52ebbd613 |